Crossmark

Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States

Crossref DOI link: https://doi.org/10.1186/s40164-018-0095-8

Published Online: 2018-02-09

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

McCrea, Charles http://orcid.org/0000-0002-4122-4268
Johal, Sukhvinder

Yang, Shuo

Doan, Justin
Funding

Funding for this research was provided by:

Bristol-Myers Squibb
More Information

Article History

Received: 22 November 2017

Accepted: 2 February 2018

First Online: 9 February 2018